---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016454"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:26:45.959343+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025

## Summary
- Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.
- Cash and securities $223.6M as of June 30, extended cash runway through 2025 via portfolio prioritization.
- BDC-1001 monotherapy/combination dose-escalation data and RP2D expected H2 2022.
- BDC-2034 discontinued due to off-target toxicity; focus on BDC-1001, BDC-3042, and next-gen ISAC.
- BDC-3042 IND-enabling studies underway; clinical start on track for 2023.

## SEC filing metadata
- accession: 0000950170-22-016454
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/0000950170-22-016454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/bolt-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016454
- JSON: https://secwatch.observer/filing/0000950170-22-016454.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.